文献速递其他结缔组织病

自体CD19靶向CAR T细胞治疗难治性幼年型皮肌炎一例

Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis.
PubMed 文献 · Arthritis Rheumatol · 2024-07-31

本文报告一例12岁白人男性重症慢性活动性幼年型皮肌炎(JDM)患者,对多种免疫抑制治疗(包括利妥昔单抗B细胞清除)难治。患者接受单次输注新鲜自体第二代抗CD19 CAR T细胞(慢病毒载体,Prodigy设备制备,1×10^6 CAR T细胞/kg),淋巴细胞清除采用环磷酰胺(1,000 mg/m2,两天)和氟达拉滨(90 mg/m2,三天)。结果显示CAR T细胞显著扩增(第7天峰值32.69个细胞/μL),第5天血液和第2周骨髓完全B细胞清除,出现轻度细胞因子释放综合征(1级)、短暂贫血(2级)和中性粒细胞减少(4级),无感染或神经毒性;8个月后持续无免疫抑制药物临床和影像学改善。

要点

  • 单次输注自体抗CD19 CAR T细胞后,该难治性JDM患者实现持续B细胞清除,8个月无免疫抑制药物临床和影像学改善。
  • 治疗相关毒性包括轻度细胞因子释放综合征(1级)、短暂贫血(2级)和中性粒细胞减少(4级),未观察到感染或神经毒性。
  • CAR T细胞输注后第7天峰值扩增至32.69个细胞/μL,第5天血液和第2周骨髓完全B细胞清除。

核心结论

  • 该重症慢性、对多种治疗难治的JDM患者,在单次输注抗CD19 CAR T细胞后8个月,实现持续B细胞清除和无免疫抑制药物的持续临床与影像学改善。

研究设计与样本

  • 病例报告:一名12岁白人男性重症慢性活动性JDM患者,对多种免疫抑制治疗线(包括利妥昔单抗B细胞清除)难治。

主要发现

  • CAR T细胞显著扩增,峰值出现在第7天,为32.69个细胞/μL。
  • 第5天血液和第2周骨髓记录到完全B细胞清除。
  • 患者出现发热作为轻度细胞因子释放综合征的一部分(1级)、短暂贫血(2级)和中性粒细胞减少(4级);未观察到感染或神经毒性。
  • 实验室检查、磁共振成像、医师疾病活动性整体评估、儿童肌炎评估量表和肌炎皮肤评估工具在基线和随访时显示显著进行性改善,且随时间持续,甚至在B细胞恢复后仍持续。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study is to report the safety and efficacy of CD19-targeting chimeric antigen receptor (CAR) T cells in a child with refractory juvenile dermatomyositis (JDM). METHODS: We describe a 12-year-old White male with severe, chronically active JDM refractory to multiple immunosuppressive treatment lines, including B cell depletion with rituximab. The patient received a single infusion of fresh, autologous, second-generation anti-CD19 CAR T cell product (lentiviral vector) manufactured on the Prodigy device (1 × 106 CAR T cells/kg), after lymphodepletion with cyclophosphamide (1,000 mg/m2 over two days) and fludarabine (90 mg/m2 over three days). Immunosuppressive and glucocorticoid treatment were withdrawn before leukapheresis and CAR T cell infusion. RESULTS: Before anti-CD19 CAR T cell therapy, the patient had persistent severe skin and muscular disease activity. CAR T cells expanded significantly (peak at day 7, 32.69 cells/μL). Complete B cell depletion was documented on day 5 in the blood and at week 2 in the bone marrow. The patient presented with fever as part of mild cytokine release syndrome (grade 1), transient anemia (grade 2), and neutropenia (grade 4). Neither infection nor neurotoxicity were observed. Laboratory tests, magnetic resonance imaging, Physician Global Assessment of disease activity, Childhood Myositis Assessment Scale, and Cutaneous Assessment Tool for myositis were performed at baseline and follow-up to assess treatment response, showing remarkable progressive improvement that persists over time, even after B cell recovery. CONCLUSION: This patient with JDM with severe chronic disease, refractory to multiple treatments, achieved sustained B cell depletion and ongoing immunosuppressive drug-free clinical and radiologic improvement eight months after a single infusion of anti-CD19 CAR T cells.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Nicolai R, Merli P, Moran Alvarez P, et al. Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis. Arthritis Rheumatol. 2024. PMID: 38924652. doi:10.1002/art.42933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。